SCHEDULE 13G 0001974915 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 06/30/2025 0001907108 Lexeo Therapeutics, Inc. 52886X107 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 Rule 13d-1(b) Vestal Point Capital, LP DE 0.00 3228161.00 0.00 3228161.00 3228161.00 N 6.0 IA PN Ryan Wilder X1 0.00 3228161.00 0.00 3228161.00 3228161.00 N 6.0 HC IN Lexeo Therapeutics, Inc. 345 Park Avenue South, Floor 6, New York, NY 10010 This statement is filed by: (i) Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Lexeo Therapeutics, Inc. (the "Company") directly held by the Vestal Point Fund and Account; and (ii) Mr. Ryan Wilder ("Mr. Wilder"), the Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Vestal Point Fund and Account. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein. The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012. The Investment Manager is a Delaware limited partnership. Mr. Wilder is a citizen of the United States. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 53,987,117 shares of Common Stock outstanding, which is the sum of: (i) 33,196,997 shares of Common Stock outstanding as of May 9, 2025, as reported in Amendment No. 1 to the Company's Quarterly Report on Form 10-Q/A for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on May 15, 2025; and (ii) 20,790,120 shares of Common Stock issued by the Company on May 27, 2025, in connection with a private placement, as described in the Current Report on Form 8-K filed with the SEC on May 27, 2025. 6.0% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). The Vestal Point Fund and Account have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1: Joint Filing Agreement Vestal Point Capital, LP /s/ Ryan Wilder 08/14/2025 Ryan Wilder /s/ Ryan Wilder 08/14/2025